Biotech Co.* (Symbol, country)

Pharma Co. (Symbol, country)

Product

Amount (M)

Terms/Details (Date)

Avanir Pharmaceuticals (OTC BB: AVNR)

SmithKline Beecham plc (NYSE:SBH)

Docosanol 10% cream in the over-the-counter market for treatment of recurrent oral-facial herpes

ND

SmithKline signed letter of intent for rights to market docosonal 10% over the counter (12/99)

AVAX Technologies Inc.

Neptunus International Holdings Ltd. (Australia)

M-Vax, an autologous cancer vaccine for melanoma

A$4 (US$2.5)

Companies created joint venture, AVAX Australia Pty. Ltd., to manufacture and market M-Vax in Australia, with similar rights for New Zealand AVAX Australia received A$4M from Neptunus for a 20% stake in the joint venture; Neptunus has an option to purchase an additional 30% interest for A$6M; AVAX has also been granted options to purchase common stock equivalent to 5% of Neptunus' shares (12/99)

Cypress Bioscience Inc.

Meduxus Inc.* (Canada)

Prosorba column therapy for rheumatoid arthritis

ND

Meduxus will apply for approval Canada and will market and distribute the product; Cypress will get the lesser of a predetermined percentage of net Canadian sales or a transfer price (12/99)

DUSA Pharmaceuticals Inc.

Schering AG (Germany)

Levulan (aminolevulin-ic acid HCl)

$23.75

Schering gains exclusive worldwide marketing and distribution rights worldwide (except Canada) for dermatology indications; DUSA will receive milestones and other payments upon signing, regulatory approval and first commercial sale, plus a $6.25M equity investment; agreement also includes research funding by Schering on new dermatology indications and pre-paid royalties following FDA approval of up to 3 additional dermatology indications; for product supply, DUSA will receive a combined royalty/supply fee based on sales (11/99)

EntreMed Inc.

Chiron Corp.

Bulk production of EntreMed's anti-genic protein, Endostatin

ND

Companies signed letter of understanding that Chiron will perform contract manufacturing of bulk Endostatin protein (12/99)

GelTex Pharmaceuticals Inc.

Sankyo Pharma Inc. (Japan) and Sankyo Parke-Davis (50-50 joint venture with Parke-Davis unit of Warner-Lambert Co.; NYSE:WLA)

Licensing and option agreement/Cholestagel (colesevelam hydrochloride), an NDA-stage product for the treat of hypercholesterol-emia, as well as more potent second-generation product, GT 102-279

$75

Sankyo will pay up to $75M, including $45M in up-front payments and milestones and $30M in funding for development of GT102-279; Sankyo receives exclusive marketing rights in the U.S. for Cholestagel for the treatment of high cholesterol and purchased an option for global rights to GT102-207; additional fees and milestones possible for GT102-207; Sankyo will also pay all development costs for second-generation compound while option is in effect; GelTex will receive royalties on all sales (11/99)

GeneFormatics Inc.*

Rikei Corp. (Japan)

Data-mining technology

ND

Rikei will invest in Gene-Formatics data-mining technology and will serve as the exclusive sales and marketing channel for the company's products and services in Japan (12/99)

Hemispherx Biopharma Inc. (AMEX:HEB)

Schering-Plough Corp. (NYSE: SGP)

Ampligen, an antiviral under development for various diseases

ND

 Schering-Plough will manufacture U.S. supplies of the drug at its facilities in San Juan, Puerto Rico; agreement may be expanded to include other territories (12/99)

Interneuron Pharmaceuticals Inc.

Madaus AG* (Germany)

Trospium chloride, a prescription drug currently marketed as a treatment for urinary incontinence

ND

Interneuron gains exclusive U.S. marketing rights in exchange for milestones and royalties; Interneuron is responsible for all clinical development and regulatory activities and costs related to the compound in the U.S. (11/99)

PathoGenesis Corp.

AMRAD Pharmaceuticals Pty. Ltd. (Australia)

TOBI (tobramycin solution for inhalation), an antibiotic for cystic fibrosis-related infections

ND

AMRAD will distribute TOBI upon regulatory approval in Australia; financial details ND (11/99)

PathoGenesis Ltd. (affiliate of PathoGenesis Corp.)

Genesis Pharma SA (member of MSJ Group; Greece)

TOBI (tobramycin solution for inhalation), an antibiotic for cystic fibrosis-related infection

ND

Genesis gains distribution rights in Greece and Cyprus upon approval in those countries; financial details ND (11/99)

Sepracor Inc.

Abbott Laboratories (NYSE:ABT)

Xopenex (levalbuterol HCl), a beta agonist for treatment of reversible bronchospasm

ND

Abbott's Ross Products Division will promote Xopenex to the pediatric market in the U.S.; Sepracor will be credited with all sales and Abbott will receive a commission on pediatric sales; each company is responsible for its own selling expenses (11/99)

SuperGen Inc.

Abbott Laboratories (NYSE:ABT)

Sales and marketing agreement/deal covers rubitecan, an oral chemotherapy compound in the camptothecin class currently in Phase III trials, and Nipent, which is already approved for hairy cell leukemia

$150

Abbott will make an up-front equity investment of between $25M and $40M, plus additional milestones that bring the total to $150M, plus roylties and U.S. profit sharing; Abbott gains exclusive distribution and promotion rights to rubitecan outside the U.S. and co-promotion rights within; Abbott will also become exclusive U.S. distributor for Nipent (SuperGen retains marketing rights for the product) (12/99)

Notes:

# This chart does not include any marketing and/or distribution agreements that involve agricultural product development. The information in the chart covers the time period between 11/1/99 - 12/31/99.

ND = Not disclosed, reported and/or available

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 21-22.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange